Search results for " dermatosi"
showing 9 items of 9 documents
Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: Real-life experience from the French CAREPI study group
2021
Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemiplimab. Endpoints were best overall response rate (BOR), progression-free survival (PFS), overall survival (OS), duration of response (DOR) and safety. The 245 patients (mean age 77 years, 73% male, 49% prior systemic treatment, 24% immunocompromised, 27% Eastern Cooperative Oncology Group performance status (PS) ≥ 2) had laCSCCs (35%) or mCSCCs (65%). For the 240 recipients of ≥1 infusion(s), the BOR was 50.4% (complete, 21%
Bericht �ber eine solit�re tuber�se Myxodermie des linken Handr�ckens
1963
Beschreibung einer lediglich im linken Handruckenbereich lokalisierten knotig-plattenartigen Myxodermie unter eingehender Demonstration und pathogenetischer Erorterung von — der mucoiden Infiltration benachbarten — obliterierenden endarteriitischen Gefasveranderungen, die auserdem durch eine Elastica-Hyperplasie ausgezeichnet sind.
Kystes trichilemmaux ossifiants multiples du cuir chevelu : un cas familial
2012
Resume Introduction Le kyste trichilemmal, egalement appele kyste pilaire, est un kyste epithelial dermique developpe aux depens du follicule pileux. Le cuir chevelu est la localisation la plus frequente de cette lesion. Les cas ossifiant et familiaux sont rares. Observation Nous rapportons un cas de kystes trichilemmaux multiples du cuir chevelu, decouverts chez femme de 61 ans ayant des antecedents familiaux. Le diagnostic a ete confirme par l’histologie de la piece operatoire. Les kystes trichilemmaux se caracterisaient par remaniements intrakystiques, sous forme d’ossification. L’etendue des lesions a necessite une exerese chirurgicale elargie du cuir chevelu. La reconstruction a ete fa…
Patologia Cutanea HCV correlata
2005
Questo review sintetizza le ormai ben note associazioni tra virus dell’epatite C (HCV) ed alcune dermatosi. Data l’opportunità di un valido trattamento per le infezioni da HCV, spesso asintomatiche, il medico deve tenere sempre presente che particolari manifestazioni cutanee possono essere la spia di infezioni da virus dell’epatite C fino a quel momento non diagnosticate e pertanto, ove necessario, procedere all’esecuzione di appropriati test di screening.
Ondansetrón. Un tratamiento satisfactorio para el prurito palmoplantar refractario
2006
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS
2013
Bariatric surgery represents a common approach for the control of severe morbid obesity, reducing caloric intake by modifying the anatomy of the gastrointestinal tract. Following jejunoileal bypass, a large spectrum of complications has been described, with rheumatic manifestation present in up to 20% of cases. Although bowel bypass syndrome, also called blind loop syndrome, is a well-recognized complication of jejunoileal bypass, the same syndrome was recognized in patients who had not had intestinal bypass surgery, and the term the 'bowel-associated dermatosis-arthritis syndrome' (BADAS) was coined. The pathogenesis of BADAS is as yet poorly understood and only few data concerning this is…
Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum
2019
Introduction: Pyoderma gangrenosum (PG) is a noninfectious, reactive inflammatory neutrophilic dermatosis that is commonly associated with autoimmune and neoplastic disorders. There are emerging diagnostic tools and treatment options for PG.Area covered: The diagnosis of PG should be seriously considered when managing ulcers to avoid unnecessary medical and surgical complications with prompt and suitable treatment. There are no standardized treatment guidelines for PG, and current therapy largely depends on the severity and progression of the disease. Systemic corticosteroids, immunosuppressant therapy, and biologic agents remain mainstay therapies. In this article, we present a literature …